MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD)
Clinical trials for MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD) explained in plain language.
Never miss a new study
Get alerted when new MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD) trials appear
Sign up with your email to follow new studies for MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial aims to tame rare neurological disease Flare-Ups
Disease control Recruiting nowThis study is testing whether the drug satralizumab can prevent relapses in people with MOG antibody-associated disease (MOGAD), a rare condition that causes inflammation in the brain and spinal cord. The trial will enroll 152 participants aged 12 and older who have had recent di…
Matched conditions: MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD)
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Scientists use Super-Powered scans to unlock Brain's secrets in aging and disease
Knowledge-focused Recruiting nowThis study aims to understand how the brain changes and adapts in various neurological conditions and during normal aging. Researchers will use advanced, high-powered MRI scans to look at brain structure, function, and energy use in 700 participants, including people with disease…
Matched conditions: MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD)
Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:15 UTC